SUPNSUPNHealthcare · Drug Manufacturers - Specialty & Generic

SUPN Stock Forecast: Supernus Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 3 Nov 2026
$28
−32.75% on the day

The 6 Wall Street analysts covering Supernus Pharmaceuticals, Inc. hold a median 12-month price target of $48 — +70.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 97 of 100 as at 2 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$6.0B
Ticker Nerd rank
97/ 100
Median analyst target
$48
Analysts covering
6
Revenue$219.1M+32.4% y/y
Operating income−$3.0M
Net income−$58.4M
Free cash flow−$5.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−31.2%
1M
−33.5%
YTD
−43.3%
1Y
−49.4%
From 52W high
−50.5%
From 52W low
0.0%
$28
$57
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

SUPN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Supernus Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 2 Nov 2026
97/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
98
Volatility
96
Accruals
90
Quality
86
Growth
84
Revisions
76
Issuance
64
Momentum
50
Size
33

Value (98): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Momentum (50): The shares have been drifting down relative to others.

Size (33): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

SUPN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SUPN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$40$60$80$100Jan 26Apr 26Jul 26Oct 26SUPNHigh $87Median $48Low $45

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says6 analysts
6 Buy0 Hold0 Sell
Low $45Median $48High $87

The green dot is the last close — the median target sits +70.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
4 Nov 2026Cantor FitzgeraldMaintainsOverweight$67 → $87
4 Nov 2026Piper SandlerReinstatesOverweight$47
28 Oct 2026BarclaysMaintainsOverweight—
5 Aug 2026BarclaysMaintainsOverweight—
9 July 2026Cantor FitzgeraldMaintainsOverweight$63 → $67
9 July 2026Cantor FitzgeraldMaintainsOverweight—
18 June 2026BarclaysInitiatesOverweight—
19 Dec 2025StifelMaintainsHold—
29 Oct 2025B of A SecuritiesInitiatesBuy—
23 Oct 2025TD CowenMaintainsBuy—
9 Oct 2025Piper SandlerUpgradeOverweight—
30 Sept 2025Cantor FitzgeraldMaintainsOverweight—
29 Aug 2025Piper SandlerMaintainsNeutral—
6 Aug 2025Cantor FitzgeraldMaintainsOverweight—
26 Feb 2025Cantor FitzgeraldReiteratesNeutral—
19 Feb 2025Cantor FitzgeraldDowngradeNeutral—
11 Sept 2024Piper SandlerDowngradeNeutral—
28 Feb 2024Piper SandlerMaintainsOverweight—
9 Nov 2023Piper SandlerMaintainsOverweight—
25 Oct 2023Piper SandlerMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

SUPN appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

SUPN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 3 Nov 2026, Supernus Pharmaceuticals, Inc. returned −49.4% against +11.6% for the S&P 500, dividends included.

SUPN vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Jan 26Apr 26Jul 26Oct 26SUPNS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SUPN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
−16.8%
Analysts raising
0
Analysts cutting
0
Fundamentals

Supernus Pharmaceuticals, Inc. (SUPN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
40.7×

Cheaper than 18% of US stocks

Price / sales
4.4×

Cheaper than 26% of US stocks

Price / book
1.6×

Cheaper than 48% of US stocks

EV / EBITDA
5.5×

Cheaper than 52% of US stocks

Growth & margins
Revenue growth (YoY)
13.4%

Higher than 61% of US stocks

Earnings growth (YoY)
226.2%

Higher than 91% of US stocks

Gross margin
84.6%

Higher than 94% of US stocks

Operating margin
46.9%

Higher than 96% of US stocks

Net margin
32.8%

Higher than 91% of US stocks

Returns & dividend
Return on equity
−3.6%

Higher than 40% of US stocks

Return on assets
29.3%

Higher than 99% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Supernus Pharmaceuticals, Inc. (SUPN) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Supernus Pharmaceuticals, Inc. has a market value of $6.0B and an enterprise value of $3.6B.

  • Revenue in the twelve months to 30 June 2026: $830.4M. The latest quarter grew 13.4% year on year.

  • Net income over the same four quarters: −$109.9M, a −13.2% net margin.

  • Diluted earnings per share, trailing twelve months: −$1.92.

  • Free cash flow in the twelve months to 30 June 2026: $18.8M.

  • Shares outstanding: 58.2M.

  • Trailing P/E: 40.7×; forward P/E: 7.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Supernus Pharmaceuticals, Inc. employs 827 people — $1.0M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 17 Nov 2026

Data provided by Twelve Data

Peers

SUPN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
SUPNSupernus Pharmaceuticals, Inc.$6.0B97
PBHPrestige Consumer Healthcare, Inc.$2.3B57
RGCRegencell Bioscience Holdings Ltd.$2.3B22
PRGOPerrigo Co. Plc$2.2B90
TRLVTrulieve Cannabis Corp.$1.9B71
XERSXeris Biopharma Holdings, Inc.$3.1B100
BCRXBioCryst Pharmaceuticals, Inc.$1.9B82

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Supernus Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SUPN news & analysis

Supernus and Indivior Complete Merger Creating a Diversified CNS Biopharmaceutical Leader

GlobeNewsWire · 2 Nov 2026positive

Supernus announced completion of its merger with Indivior Pharmaceuticals, launching Supernus, Inc. as a diversified biopharmaceutical company focused on central nervous system diseases.

Why it matters — The completed merger changes the company’s corporate structure and brings together Supernus and Indivior under Supernus, Inc.

Supernus Pharmaceuticals, Inc. (SUPN) Q3 2026 Earnings Call Transcript

Seeking Alpha · 30 Oct 2026neutral

The provided text identifies a Seeking Alpha transcript of Supernus Pharmaceuticals’ Q3 2026 earnings call but does not include any details from the call.

Why it matters — SUPN watchers may note the earnings-call transcript as a source, but the excerpt provides no company updates or results to assess.

Supernus Pharmaceuticals (SUPN) Beats Q3 Earnings and Revenue Estimates

Zacks Investment Research · 30 Oct 2026positive

Supernus Pharmaceuticals reported quarterly earnings of $0.93 per share, above the Zacks Consensus Estimate of $0.49. Earnings were $1.01 per share a year earlier.

Why it matters — The results provide SUPN watchers with an update on quarterly earnings relative to analyst consensus and the prior-year period.

Supernus Pharmaceuticals Q3 Earnings Call Highlights

MarketBeat · 29 Oct 2026positive

Supernus Pharmaceuticals reported record third-quarter revenue and higher sales across its growth portfolio. Management said the planned merger with Indivior Pharmaceuticals is expected to close Nov. 2, following shareholder approvals.

Why it matters — The update highlights SUPN’s quarterly performance and the anticipated timing of its planned merger.

Supernus Announces Third Quarter 2026 Financial Results

GlobeNewsWire · 29 Oct 2026neutral

Supernus Pharmaceuticals announced its financial results for the third quarter of 2026 and reported associated company developments.

Why it matters — The announcement provides SUPN watchers with an update on the company’s quarterly financial results and developments.

FAQ

Frequently asked questions about SUPN stock

What is the SUPN stock price forecast for 2026-2027?

The 6 Wall Street analysts covering Supernus Pharmaceuticals, Inc. have a median 12-month price target of $48, with estimates ranging from $45 to $87. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SUPN stock a buy right now?

Of the 6 analysts covering Supernus Pharmaceuticals, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Supernus Pharmaceuticals, Inc. 97 out of 100 across roughly 4,600 US stocks as at 2 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SUPN?

As at 2 Nov 2026, Supernus Pharmaceuticals, Inc. ranks 97 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (98 of 100).

Will SUPN stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +70.3% from the last close, and Ticker Nerd's factor model ranks Supernus Pharmaceuticals, Inc. 97 out of 100 as at 2 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SUPN stock forecast for 2030?

No analyst covering Supernus Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SUPN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $45 to $87 over the next 12 months.

How has SUPN stock performed over the past year?

Supernus Pharmaceuticals, Inc. returned -49.4% over the 12 months to 3 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Supernus Pharmaceuticals, Inc. do?

Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for central nervous system diseases.

What is the latest news on SUPN?

The most recent item we track (GlobeNewsWire, 2 Nov 2026): "Supernus and Indivior Complete Merger Creating a Diversified CNS Biopharmaceutical Leader". Supernus announced completion of its merger with Indivior Pharmaceuticals, launching Supernus, Inc. as a diversified biopharmaceutical company focused on central nervous system diseases.

Company

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for central nervous system diseases. Supernus Pharmaceuticals, Inc. markets therapies for neurological and psychiatric conditions such as attention-deficit hyperactivity disorder, epilepsy, migraine, Parkinson’s disease-related symptoms, cervical dystonia, chronic sialorrhea, and postpartum depression. Its current portfolio includes branded medicines used in neurology and psychiatry, with products sold primarily in the United States through specialty commercial channels. The company also maintains research and development programs aimed at advancing new CNS treatments and strengthening its neuroscience portfolio. Headquartered in Rockville, Maryland, Supernus Pharmaceuticals, Inc. plays a notable role in the specialty pharmaceutical market by addressing a broad range of chronic and complex disorders affecting the central nervous system.

CEO Mr. Jack A. Khattar M.B.A. · 827 employees · United States · https://www.supernus.com